MiR-21 promotes fibrosis in an acute cardiac allograft transplantation model

Cardiovascular Research

Volumn 110, Issue 2, 2016, Pages 215-226

  Gupta, Shashi Kumar ^a   Itagaki, Ryo ^b   Zheng, Xiang ^a   Batkai, Sandor ^a   Thum, Sabrina ^a   Ahmad, Fareed ^a   Van Aelst, Lucas N ^c   Sharma, Amit ^a   Piccoli, Maria Teresa ^a   Weinberger, Florian ^d   Fiedler, Jan ^a   Heuser, Michael ^a   Heymans, Stephane ^c,e   Falk, Christine S ^a,f   Förster, Reinhold ^a   Schrepfer, Sonja ^b   Thum, Thomas ^a,g  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HEART CENTER HAMBURG   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d LPT Laboratory of Pharmacology and Toxicology   (Germany)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^g NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Allograft; Cardiac transplantation; Fibrocyte; Fibrosis; MiRNA 21

Indexed keywords

INTERLEUKIN 6; MICRORNA 21; MONOCYTE CHEMOTACTIC PROTEIN 1; CHEMOKINE; MICRORNA; MIRN21 MICRORNA, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SELECTION; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; RAW 264.7 CELL LINE; UPREGULATION; ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CARDIAC MUSCLE; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENETICS; GRAFT SURVIVAL; HEART DISEASE; METABOLISM; PATHOLOGY; PROCEDURES;

ALLOGRAFTS; ANIMALS; CHEMOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; GRAFT SURVIVAL; HEART DISEASES; HEART TRANSPLANTATION; INTERLEUKIN-6; MICE, INBRED BALB C; MICE, INBRED C57BL; MICRORNAS; MYOCARDIUM; TRANSPLANTATION, HOMOLOGOUS;

EID: 84966539975     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw030     Document Type: Article

References (28)

1. Goland S, Siegel RJ, Burton K, De Robertis MA, Rafique A, Schwarz E, Zivari K, Mirocha J, Trento A, Czer LS. Changes in left and right ventricular function of donor hearts during the first year after heart transplantation. Heart 2011;97:1681-1686.
2. Kobashigawa JA, Itagaki BK, Razi RR, Patel JK, Chai W, Kawano MA, Goldstein Z, Kittleson MM, Fishbein MC. Correlation between myocardial fibrosis and restrictive cardiac physiology in patients undergoing retransplantation. Clin Transplant 2013;27: E679-E684.
3. Pichler M, Rainer PP, Schauer S, Hoefler G. Cardiac fibrosis in human transplanted hearts is mainly driven by cells of intracardiac origin. J Am Coll Cardiol 2012;59: 1008-1016.
4. Fan D, Takawale A, Lee J, Kassiri Z. Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair 2012;5:15.
5. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 2011;11:427-435.
6. Thum T. Noncoding RNAs and myocardial fibrosis. Nat Rev Cardiol 2014;11:655-663.
7. Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol 2011;8:706-713.
8. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984.
9. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol 2012;32:361-369.
10. Hasegawa T, Visovatti SH, Hyman MC, Hayasaki T, Pinsky DJ. Heterotopic vascularized murine cardiac transplantation to study graft arteriopathy. Nat Protoc 2007;2:471-480.
11. Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, Li J, Tran PT, Kaimal V, Huang X, Chang AN, Li S, Kalra A, Grafals M, Portilla D, MacKenna DA, Orkin SH, Duffield JS. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012;4:121ra18.
12. Sharma A, Yun H, Jyotsana N, Chaturvedi A, Schwarzer A, Yung E, Lai CK, Kuchenbauer F, Argiropoulos B, Gorlich K, Ganser A, Humphries RK, Heuser M. Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia 2015;29:157-168.
13. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
14. Diaz JA, Booth AJ, Lu G,Wood SC, Pinsky DJ, Bishop DK. Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection. Am J Transplant 2009;9: 1773-1783.
15. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J, Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, Cvijic H, Ullmann AK, Stadler PF, Horn F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007; 110:1330-1333.
16. Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J, Taffet GE, Entman ML. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 2010;49:499-507.
17. Zhou J,Wang KC,WuW, Subramaniam S, Shyy JY, Chiu JJ, Li JY, Chien S. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc Natl Acad Sci USA 2011;108: 10355-10360.
18. Lee SK, Kim BS, Yang WS, Kim SB, Park SK, Park JS. High glucose induces MCP-1 expression partly via tyrosine kinase-AP-1 pathway in peritoneal mesothelial cells. Kidney Int 2001;60:55-64.
19. Zhang Z, Zha Y, Hu W, Huang Z, Gao Z, Zang Y, Chen J, Dong L, Zhang J. The autoregulatory feedback loop of microRNA-21/programmed cell death protein 4/activation protein-1 (MiR-21/PDCD4/AP-1) as a driving force for hepatic fibrosis development. J Biol Chem 2013;288:37082-37093.
20. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, Di Lauro R, Verde P. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene 2009;28:73-84.
21. Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, Aggarwal BB, Yung WK. PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway. Mol Cell Biochem 2007;300:77-87.
22. McDonald RA, Halliday CA, Miller AM, Diver LA, Dakin RS, Montgomery J, McBride MW, Kennedy S, McClure JD, Robertson KE, Douglas G, Channon KM, Oldroyd KG, Baker AH. Reducing in-stent restenosis: therapeutic manipulation of miRNA in vascular remodeling and inflammation. J Am Coll Cardiol 2015;65:2314-2327.
23. Moreau A, Varey E, Anegon I, Cuturi MC. Effector mechanisms of rejection. Cold Spring Harb Perspect Med 2013;3:doi:10.1101/cshperspect.a015461.
24. Duong Van Huyen JP, Tible M, Gay A, Guillemain R, Aubert O, Varnous S, Iserin F, Rouvier P, Francois A, Vernerey D, Loyer X, Leprince P, Empana JP, Bruneval P, Loupy A, Jouven X. MicroRNAs as non-invasive biomarkers of heart transplant rejection. Eur Heart J 2014.
25. Anglicheau D, Sharma VK, Ding R, Hummel A, Snopkowski C, Dadhania D, Seshan SV, Suthanthiran M. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci USA 2009;106:5330-5335.
26. Russell ME, Adams DH, Wyner LR, Yamashita Y, Halnon NJ, Karnovsky MJ. Early and persistent induction of monocyte chemoattractant protein 1 in rat cardiac allografts. Proc Natl Acad Sci USA 1993;90:6086-6090.
27. Fleury S, Li J, Simeoni E, Fiorini E, von Segesser LK, Kappenberger L, Vassalli G. Gene transfer of RANTES and MCP-1 chemokine antagonists prolongs cardiac allograft survival. Gene Ther 2006;13:1104-1109.
28. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, Vander Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368:1685-1694.